Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

American Academy of Neurology and American Epilepsy Society guidelines for treating of epilepsy

27.04.2004


Treatment guidelines for epilepsy evaluate antiepileptic drugs



The number of drugs available to treat epilepsy have more than doubled in the last decade. The American Academy of Neurology and the American Epilepsy Society have assembled the top experts in the field to evaluate the available data of more than 1,400 research articles in order to create a guideline for the treatment of epilepsy with these new antiepileptic drugs (AEDs).

"These guidelines are designed to provide evidence-based assessments on the use of the new anti-epileptic drugs to clinicians," said Jacqueline French, M.D., professor of neurology at the University of Pennsylvania School of Medicine in Philadelphia and one of the authors of the guidelines.


"The guidelines offer a rigorous, comprehensive and unbiased analysis of the available data on the safety, efficacy and mode of use of these AEDs that the clinician can use in making treatment decisions," said Andres Kanner, M.D., professor of neurological sciences at Rush University Medical Center in Chicago and another author of the guidelines. "This thorough review of the current research on epilepsy can also have a major impact on deciding what our priorities for future research should be," he said.

Dr. French and Dr. Kanner spoke today at an American Medical Association media briefing in partnership with the American Academy of Neurology (AAN) and the American Epilepsy Society at the AAN’s annual meeting in San Francisco.

Because of their previous experience with the older anti-epileptic drugs, doctors are comfortable using them. They need guidance in how and when to use the newer drugs. "There has been an explosion in the field of epilepsy research in the last decade," said Dr. French. "Eight new drugs have been added to the five previously approved drugs commonly used for the treatment of epilepsy. While the older drugs are all effective in preventing seizures, there are some concerns about side effects over the long term."

"Epilepsy often strikes when people are young and patients will be on medication for decades," said Dr. French. "The older drugs are all known to have significant impact on liver metabolism which can affect other drugs a patient takes as well as the body’s own hormone metabolism. Other possible side effects include osteoporosis, sleepiness and confusion. These new drugs may offer a significantly better day-to-day quality of life for the patient who must take them for years."

"Usually when we see a whole new set of drugs approved for treating a condition, they are similar to one another," said Dr. French. "This is a different situation entirely. Each of these new anti-epileptic drugs has an absolutely unique mode of action, unique side effect profile and an unique set of drug interactions. There is great deal of information for the practicing physician to sift through to use these drugs safely and effectively."

There are actually two sets of guidelines, one to treat newly diagnosed epilepsy and one to treat epilepsy that has already proved difficult to manage with the older drugs. "The FDA drug approval process, which requires placebo (or near-placebo) -controlled trials, makes it very difficult to gather some of the kinds of information we need," said Dr. French. "With a life-threatening illness, it is not possible to take people off all medications. We have to use other evidence of effectiveness, as well as European trials where new drugs are compared to older medications, to do our analysis."

"The European equivalent of the FDA has years of studies that provide us with a lot of good data on safety and efficacy of these new AEDs," said Dr. Kanner. "With so many new drugs and an absence of head-to-head comparison studies, we have to rely on on this type of evidence-based assessment of all the available information to give the practicing physician a better way to make a treatment choice."

"For patients who may find themselves paying more for the newer drugs, it is important that they can feel comfortable that the safety and efficacy of these new drugs have been analyzed in an objective and rigorous manner and are being used in an appropriate way," said Dr. Kanner. "There is a real concern in the media today that too much of the information reaching doctors about new drugs may come only from the pharmaceutical industry. These guidelines provide the clinician with an assessment that is in no way driven by the marketplace."


To contact Jacqueline French, M.D., contact Karen Kreeger at 215-349-5658 or karen.kreeger@uphs.upenn.edu. To contact Andrew Kanner, M.D., contact John Pontarelli at 312-942-5949 or jpontare@rush.edu. On the day of the briefing, call the AMA’s Science News Department at 312-464-2410, the AAN Press Room at 415-978-3521, or email kstone@aan.com.

Karen Kreeger | EurekAlert!
Further information:
http://www.ama-assn.org/

More articles from Health and Medicine:

nachricht GLUT5 fluorescent probe fingerprints cancer cells
20.04.2018 | Michigan Technological University

nachricht Scientists re-create brain neurons to study obesity and personalize treatment
20.04.2018 | Cedars-Sinai Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: BAM@Hannover Messe: innovative 3D printing method for space flight

At the Hannover Messe 2018, the Bundesanstalt für Materialforschung und-prüfung (BAM) will show how, in the future, astronauts could produce their own tools or spare parts in zero gravity using 3D printing. This will reduce, weight and transport costs for space missions. Visitors can experience the innovative additive manufacturing process live at the fair.

Powder-based additive manufacturing in zero gravity is the name of the project in which a component is produced by applying metallic powder layers and then...

Im Focus: Molecules Brilliantly Illuminated

Physicists at the Laboratory for Attosecond Physics, which is jointly run by Ludwig-Maximilians-Universität and the Max Planck Institute of Quantum Optics, have developed a high-power laser system that generates ultrashort pulses of light covering a large share of the mid-infrared spectrum. The researchers envisage a wide range of applications for the technology – in the early diagnosis of cancer, for instance.

Molecules are the building blocks of life. Like all other organisms, we are made of them. They control our biorhythm, and they can also reflect our state of...

Im Focus: Spider silk key to new bone-fixing composite

University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

Im Focus: Gamma-ray flashes from plasma filaments

Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.

The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur

09.04.2018 | Event News

 
Latest News

Getting electrons to move in a semiconductor

25.04.2018 | Physics and Astronomy

Reconstructing what makes us tick

25.04.2018 | Physics and Astronomy

Cheap 3-D printer can produce self-folding materials

25.04.2018 | Information Technology

VideoLinks
Science & Research
Overview of more VideoLinks >>>